Validation of ultrafiltration as a method of measuring free 99mTc-MDP

Journal of Nuclear Medicine

Volumn 44, Issue 6, 2003, Pages 891-897

  Moore, Amelia E B ^a   Hain, Sharon F ^a   Blake, Glen M ^a   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

99mTc methylene diphosphonate; Glomerular filtration rate; Ultrafiltration

Indexed keywords

EDETATE CHROMIUM CR 51; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD SAMPLING; BONE SCINTISCANNING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ELIMINATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULTRAFILTRATION; URINALYSIS; VALIDATION PROCESS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METHODOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; URINE; VALIDATION STUDY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RADIOPHARMACEUTICALS; REFERENCE VALUES; TECHNETIUM TC 99M MEDRONATE; ULTRAFILTRATION;

EID: 0038162370     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene disphosphonate: a superior agent for skeletal imaging - comparison with other technetium complexes. J Nucl Med. 1975;16:744-755.
2. 18F-Fluoride for bone imaging. Semin Nucl Med. 1972;2:31-37.
3. 99mTc-methylene diphosphonate Semin Nucl Med. 2001;31:28-49.
4. Fogelman I, Bessent RG, Turner JG, et al. The use of whole-body retention of Tc-99m disphosphonate in the diagnosis of metabolic bone disease J Nucl Med 1978;19:270-275.
5. Hyldstrup L, Mogensen N, Jensen GF, et al. Urinary 99m-Tc-diphosphonate excretion as a simple method to quantify bone metabolism Scand J Clin Lab Invest. 1984;44:105-109.
6. Thomsen K, Nilas L, Mogensen T, et al. Determination of bone turnover by urinary excretion of 99m-Tc-MDP Eur J Nucl Med. 1986;12:342-345.
7. 18F]fluoride kinetics in humans. J Nucl Med 1978;19:301-1309.
8. Makler PT Jr, Charkes ND. Studies of skeletal tracer kinetics. IV. Optimum time delay for Tc-99m(Sn) methylene disphosphonate bone imaging. J Nucl Med. 1980;21:641-645.
9. Charkes ND, Seigel JA. An analytical solution set for a four-compartment mixed mammillary/catenary model. Nucl Med Commun. 1999;20:575-580.
10. D'Addabbo A, Rubini G, Mele M, et al. A new method of assessing Tc-99m-MDP bone uptake from a bone scan image: quantitative measurement of radio-activity in global skeletal region of interest. Nucl Med Commun. 1992;13:55-60.
11. Brenner W, Bohuslavizki KH, Sieweke N, et al Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med 1997;24:1284-1290.
12. Carnevale V, Frusciante V, Scillitam A, et al Age-related changes in the global skeletal uptake of technetium-99m methylene disphosphonate in healthy women Eur J Nucl Med. 1996;23:1473-1477.
13. 99mTc-technetium methylene disphosphonate with age: relevance to the pathogenesis of bone loss. J Nucl Med. 2000;41:1478-1483.
14. Hawkins RA, Choi Y, Huang S-C, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med. 1992;33:633-642.
15. Schiepers C, Nuyts J, Bormans G, et al. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. J Nucl Med. 1997;38:1970-1976.
16. 18F-fluoride positron emission tomography in postmenopausal women. J Bone Miner Res. 2000;15:763-769
17. 18F- fluoride positron emission tomography J Bone Miner Res 2002;17:854-859.
18. Budinger TF. PET instrumentation: what are the limits? Semin Nucl Med. 1998;28:247-267.
19. Chen PS, Smith FA, Gardiner DE, et al. Renal clearance of fluoride. Proc Soc Exp Biol Med. 1956;92:879-883.
20. Carlson CH, Armstrong WD, Singer L. Distribution, migration and binding of whole blood fluoride evaluated with radiofluoride Am J Physiol 1960;199:187-189
21. Taves DR. Electrophoretic mobility of serum fluoride. Nature. 1968;220:582-583.
22. Hyldstrup L, McNair P, Ring P. Studies on diphosphonate kinetics. Part I. Evaluation of plasma elimination curves during 24 h. Eur J Nucl Med. 1987;12:581-584
23. 99mTc-methylene diphosphonate evaluation of renal and whole-blood kinetics. Nucl Med Commun. 2001;22:1037-1044.
24. 99mTc-methylene diphosphonate protein binding. Nucl Med Commun. In press
25. Jeghers O, Piepsz A, Ham HR. What does protein binding of radiopharmaceuticals plasma mean exactly? Eur J Nucl Med. 1990;17:101-102.
26. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer. 2001;84:452-459.
27. Bailey DL, Hain SF, Adamson KL, et al. Quantitative dynamic bone SPECT: a new method to assess skeletal kinetics [abstract]. J Nucl Med. 2003;44(suppl). 150P.
28. Gluer C-C, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporosis Int. 1995;5:262-270.
29. 99mTc- methylene diphosphonate J Nucl Med. 2002;43:338-345.
30. Vanlicrazumenic N, Joksimovic J, Ristic B, Tomic M, Beatovc S, Ajdinovic B. Interaction of Tc-99m-radiopharmaceuticals with transport proteins in human blood. Nucl Med Biol. 1993;20:363-365.